ClinicalTrials.gg
Not yet recruitingNCT07608172Updated May 27, 2026

Short-Course Regimens for DS-PTB in AIDS Patients

An interventional study of 2HPMZ/2HPM and 2HRZE/4HR in Tuberculosis in HIV-infected Individuals and Drug Susceptible Pulmonary Tuberculosis, sponsored by Shanghai Public Health Clinical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Primary conditionTuberculosis, PulmonaryRegistry: TuberculosisReclassifiedWhy we changed it
Registry
Tuberculosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tuberculosis, Pulmonary
Why
  1. The study's listed conditions name Tuberculosis, Pulmonary, a narrower term within Tuberculosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Public Health Clinical Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study adopts a multicenter, open-label, randomized controlled design, conducted across key designated AIDS diagnosis and treatment hospitals nationwide. It aims to compare the efficacy and safety of the 2HPMZ/2HPM regimen versus the 2HRZE/4HR regimen in treating HIV-associated drug-susceptible pulmonary tuberculosis (DS-TB) among patients with a CD4+ T-cell count \< 100 cells/μL. A total of 148 participants will be enrolled and randomized 1:1 into two groups: 74 cases in the 2HPMZ/2HPM group and 74 cases in the 2HRZE/4HR group.

02

Conditions studied

  • Tuberculosis in HIV-infected Individuals
  • Drug Susceptible Pulmonary Tuberculosis

Browse trials for

Keywords

  • Drug susceptible pulmonary tuberculosis
  • HIV-infected individuals
  • 2HPMZ/2HPM
03

In context

Tuberculosis, Pulmonary Reclassified

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

This study's planned enrollment of 148 is close to the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.

Browse Tuberculosis, Pulmonary studies →

Lead sponsor

Shanghai Public Health Clinical Center is the lead sponsor of 38 studies on the registry; 11 are open to participants now.

Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years, able to understand and sign the form.
  • Confirmed infection.
  • Baseline \< 100 cells/μL.
  • Confirmed active pulmonary tuberculosis.
  • Agree to receive antituberculosis treatment and antiretroviral therapy during the study period.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected resistance to any of the drugs in the regimen, including rifapentine, moxifloxacin, rifampicin, isoniazid, ethambutol, and pyrazinamide.
  • Body weight \< 40 kg.
  • Received the current tuberculosis treatment for more than 7 days.
  • Complicated with tuberculous meningitis or other severe forms of tuberculosis.
  • Severe liver dysfunction ( or AST > 5 times the , ULN). - - Severe renal dysfunction ( \< 30 mL/min/1.73m²).
  • Baseline (ECG) showing > 500 ms.
  • Pregnant or lactating women.
  • Presence of other conditions deemed inappropriate for study participation by the investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    2HPMZ/2HPM

    8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin.

    Drug: 2HPMZ/2HPM

  • Active comparator
    2HRZE/4HR

    2HRZE/4HR

    Drug: 2HRZE/4HR

Interventions

  • Drug2HPMZ/2HPM

    8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin

  • Drug2HRZE/4HR

    2 months of isoniazid, rifampin, pyrazinamide, and ethambutol followed by 4 months of isoniazid and rifampin

06

What researchers measure

Primary outcomes

  1. All-cause mortality at Month 12

    Record the date of death and primary cause of death.

    Time frame: 12 month

Secondary outcomes

  1. The rate of IRIS

    Clinical symptoms and laboratory indicators

    Time frame: At Baseline, Week 4, Week 8, Week 12, Week 18, Week 24 and Week 48.

  2. Sputum culture negative conversion rate at the end of the 2nd month

    Microbiological outcome of sputum culture

    Time frame: at the end of the 2nd month

  3. The rates of AE and SAE

    Adverse envents (AEs) will be graded according to CTCAE version 5.0, and the AE name, grade, causality, and outcome will be recorded.

    Time frame: At Baseline, Week 4, Week 8, Week 12, Week 18, Week 24 and Week 48.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2028, 25 months later.

Of 42 non-industry interventional studies with no phase under Tuberculosis, Pulmonary, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 25 months is above that.

Counting every sponsor, half of 42 studies reached it within 17 months; a quarter within 11 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 27, 2026
StartEst.
May 25, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07608172
Lead sponsor
Shanghai Public Health Clinical Center
Collaborators
Beijing Ditan Hospital, Guangzhou eighth People's Hospital ,Guangzhou Medilcal University, The Second Hospital of Nanjing Medical University, Chengdu Public Health Clinical Center, The Third People's Hospital of Yunnan Province, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Peking Union Medical College Hospital, Beijing YouAn Hospital, The First Affiliated Hospital of Zhengzhou University, Guiyang Public Health Clinical Center, Chongqing Public Health Medical Center, Chest Hospital of Guangxi Zhuang Autonomous Region
Responsible party
Yinzhong Shen (Professor, Shanghai Public Health Clinical Center) — Principal investigator
First posted
May 27, 2026
Start date
May 25, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 27, 2026

Study contacts

Yinzhong Shen, Professor
Contact
Shenyinzhong@shphc.org.cn
+86 18916113951

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion